DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
1 . An intranasal device for administration of a pharmaceutical composition comprising:
a reservoir and a means for discharging one or more doses of the pharmaceutical composition, wherein the reservoir contains a quantity of the pharmaceutical composition;
wherein the pharmaceutical composition is a dry powder comprising:
epinephrine or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition provides a dose of about 15 mg to about 40 mg of the epinephrine or the pharmaceutically acceptable salt thereof,
citric acid or a pharmaceutically acceptable salt thereof,
a carrier; and
wherein the pharmaceutical composition does not include an additional vasodilator.
2 . The intranasal device of claim 1 , wherein the intranasal device is stored within a defibrillator, wherein the defibrillator is configured to determine a cardiac rhythm of a patient upon activation of the defibrillator and placement of at least one defibrillator pad on the chest of the patient, wherein the application of the pharmaceutical composition is recommended via audio emitted by the defibrillator.
3 . The intranasal device of claim 2 , wherein the defibrillator is configured to detect the removal of the intranasal device from the defibrillator, wherein upon detection of the removal of the intranasal device the defibrillator emits instructional audio including at least one instruction for the use of the intranasal device.
4 . The intranasal device of claim 1 , wherein a median particle diameter of the epinephrine or the pharmaceutically acceptable salt thereof is about 20 μm to about 75 μm.
5 . The intranasal device of claim 1 , wherein the pharmaceutical composition further comprises one or more agents selected from a group consisting of a mucosal permeation or penetration enhancer, a mucoadhesive, a mucosal transit slowing agent, a mucosal transport enhancer, or any combination thereof.
6 . The intranasal device of claim 1 , wherein the intranasal device further includes an intranasal device global positioning system (GPS) device or is coupled to a GPS device, wherein the intranasal device GPS or the GPS device is constructed and configured to provide location data.
7 . The intranasal device of claim 1 , wherein the intranasal device further includes a communications interface, wherein the communications interface is constructed and configured to transmit data wirelessly to at least one remote device.
8 . The intranasal device of claim 1 , wherein the carrier includes mannitol, a cyclodextrin, citric acid, lactose, and/or sodium carboxymethylcellulose.
9 . The intranasal device of claim 1 , wherein the pharmaceutical composition does not include a preservative.
10 . The intranasal device of claim 1 , wherein the quantity of the pharmaceutical composition is between about 5 mg and about 75 mg.
11 . The intranasal device of claim 1 , wherein the intranasal device further includes a sensor that is adapted to detect a displacement or a deformation of a portion of the intranasal device when the dry powder is dispensed from the reservoir.
12 . A kit for intranasal administration of a pharmaceutical composition comprising:
at least one intranasal device, wherein each of the at least one intranasal device includes a reservoir and a means for discharging one or more doses of the pharmaceutical composition, wherein the reservoir contains a quantity of the pharmaceutical composition; and
a pouch and/or a hard case, wherein the at least one intranasal device is enclosed in the pouch and/or the hard case;
wherein the pharmaceutical composition is a dry powder comprising:
epinephrine or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition provides a dose of about 15 mg to about 40 mg of the epinephrine or the pharmaceutically acceptable salt thereof,
citric acid or a pharmaceutically acceptable salt thereof,
a carrier; and
wherein the pharmaceutical composition does not include an additional vasodilator.
13 . The kit of claim 12 , wherein the kit further includes a defibrillator, wherein the defibrillator is configured to determine a cardiac rhythm of a patient upon activation of the defibrillator and placement of at least one defibrillator pad on the chest of the patient, wherein the application of the pharmaceutical composition is recommended via audio emitted by the defibrillator.
14 . The kit of claim 13 , wherein the defibrillator is configured to detect the removal of the intranasal device from the defibrillator, wherein upon detection of the removal of the intranasal device the defibrillator emits instructional audio including at least one instruction for the use of the intranasal device.
15 . The kit of claim 12 , wherein the quantity of the pharmaceutical composition is between about 5 mg and about 75 mg.
16 . The kit of claim 12 , wherein the pouch and/or the hard case is Modular Lightweight Load-carrying Equipment (MOLLE)-compatible.
17 . An intranasal device for administration of a pharmaceutical composition comprising:
a reservoir and a means for discharging one or more doses of the pharmaceutical composition, wherein the reservoir contains a quantity of the pharmaceutical composition;
wherein the pharmaceutical composition is a dry powder comprising:
epinephrine or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition provides a dose of about 15 mg to about 40 mg of the epinephrine or the pharmaceutically acceptable salt thereof,
citric acid or a pharmaceutically acceptable salt thereof, and
a carrier;
wherein the pharmaceutical composition does not include an additional vasodilator;
wherein the intranasal device is stored within a defibrillator;
wherein the defibrillator is configured to emit an audio message; and
wherein the audio message includes at least one instruction for administering the pharmaceutical composition via the intranasal device.
18 . The intranasal device of claim 17 , wherein the defibrillator is configured to determine a cardiac rhythm of a patient upon activation of the defibrillator and placement of at least one defibrillator pad on the chest of the patient, wherein the audio message emitted by the defibrillator includes a recommended treatment method based on the cardiac rhythm of the patient.
19 . The intranasal device of claim 17 , wherein the defibrillator is configured to detect the removal of the intranasal device from the defibrillator, wherein the audio message is emitted upon detection of the removal of the intranasal device.
20 . The intranasal device of claim 17 , wherein the pharmaceutically acceptable salt of citric acid is monosodium citrate, disodium citrate, or trisodium citrate.